159 related articles for article (PubMed ID: 28893415)
1. The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy.
Cox S; Hurt C; Grenader T; Mukherjee S; Bridgewater J; Crosby T
Radiother Oncol; 2017 Oct; 125(1):154-159. PubMed ID: 28893415
[TBL] [Abstract][Full Text] [Related]
2. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
Crosby T; Hurt CN; Falk S; Gollins S; Mukherjee S; Staffurth J; Ray R; Bashir N; Bridgewater JA; Geh JI; Cunningham D; Blazeby J; Roy R; Maughan T; Griffiths G
Lancet Oncol; 2013 Jun; 14(7):627-37. PubMed ID: 23623280
[TBL] [Abstract][Full Text] [Related]
3. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.
Crosby T; Hurt CN; Falk S; Gollins S; Staffurth J; Ray R; Bridgewater JA; Geh JI; Cunningham D; Blazeby J; Roy R; Maughan T; Griffiths G; Mukherjee S
Br J Cancer; 2017 Mar; 116(6):709-716. PubMed ID: 28196063
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
Zhou XL; Li YQ; Zhu WG; Yu CH; Song YQ; Wang WW; He DC; Tao GZ; Tong YS
Sci Rep; 2017 Feb; 7():42581. PubMed ID: 28195186
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer.
Yoo EJ; Park JC; Kim EH; Park CH; Shim CN; Lee HJ; Chung HS; Lee H; Shin SK; Lee SK; Lee CG; Lee YC
Dig Liver Dis; 2014 Sep; 46(9):846-53. PubMed ID: 24970014
[TBL] [Abstract][Full Text] [Related]
6. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT
Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534
[TBL] [Abstract][Full Text] [Related]
7. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
Wood G; Grenader T; Nash S; Adams R; Kaplan R; Fisher D; Maughan T; Bridgewater J
Anticancer Drugs; 2017 Jun; 28(5):546-550. PubMed ID: 28252533
[TBL] [Abstract][Full Text] [Related]
8. Baseline derived neutrophil-to-lymphocyte ratio as a prognostic biomarker for non-colorectal gastrointestinal cancer patients treated with immune checkpoint blockade.
Li S; Zou J; Liu C; Jiao X; Gong J; Li J; Wang Z; Lu M; Lu Z; Shen L
Clin Immunol; 2020 Mar; 212():108345. PubMed ID: 31953149
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.
van Soest RJ; Templeton AJ; Vera-Badillo FE; Mercier F; Sonpavde G; Amir E; Tombal B; Rosenthal M; Eisenberger MA; Tannock IF; de Wit R
Ann Oncol; 2015 Apr; 26(4):743-749. PubMed ID: 25515657
[TBL] [Abstract][Full Text] [Related]
10. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
11. Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study.
Grenader T; Nash S; Adams R; Kaplan R; Fisher D; Maughan T; Bridgewater J
Br J Cancer; 2016 Mar; 114(6):612-5. PubMed ID: 26889974
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).
Tomblyn MB; Goldman BH; Thomas CR; Benedetti JK; Lenz HJ; Mehta V; Beeker T; Gold PJ; Abbruzzese JL; Blanke CD;
J Thorac Oncol; 2012 May; 7(5):906-12. PubMed ID: 22481235
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
[TBL] [Abstract][Full Text] [Related]
14. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.
Grenader T; Nash S; Plotkin Y; Furuse J; Mizuno N; Okusaka T; Wasan H; Valle J; Bridgewater J
Ann Oncol; 2015 Sep; 26(9):1910-1916. PubMed ID: 26037798
[TBL] [Abstract][Full Text] [Related]
15. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial.
Suntharalingam M; Winter K; Ilson D; Dicker AP; Kachnic L; Konski A; Chakravarthy AB; Anker CJ; Thakrar H; Horiba N; Dubey A; Greenberger JS; Raben A; Giguere J; Roof K; Videtic G; Pollock J; Safran H; Crane CH
JAMA Oncol; 2017 Nov; 3(11):1520-1528. PubMed ID: 28687830
[TBL] [Abstract][Full Text] [Related]
16. Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Ogul A; Kidi MM; Buyuksimsek M
J Gastrointest Cancer; 2021 Mar; 52(1):294-299. PubMed ID: 32495108
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiation-induced changes in systemic inflammatory markers and their prognostic significance in oesophageal squamous cell carcinoma.
Khin NS; Tan SH; Wang ML; Siow TR; Lim FL; Wang FQ; Ng MC; Lam JY; Yip C
Br J Radiol; 2021 Jun; 94(1122):20200314. PubMed ID: 33861156
[TBL] [Abstract][Full Text] [Related]
18. Prechemotherapy neutrophil : lymphocyte ratio is superior to the platelet : lymphocyte ratio as a prognostic indicator for locally advanced esophageal squamous cell cancer treated with neoadjuvant chemotherapy.
Ji WH; Jiang YH; Ji YL; Li B; Mao WM
Dis Esophagus; 2016 Jul; 29(5):403-11. PubMed ID: 25625421
[TBL] [Abstract][Full Text] [Related]
19. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Huang CC; Shih LH; Chen SW; Li SH
BMC Cancer; 2018 Aug; 18(1):837. PubMed ID: 30126380
[TBL] [Abstract][Full Text] [Related]
20. High expression of long non-coding RNA AFAP1-AS1 predicts chemoradioresistance and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
Zhou XL; Wang WW; Zhu WG; Yu CH; Tao GZ; Wu QQ; Song YQ; Pan P; Tong YS
Mol Carcinog; 2016 Dec; 55(12):2095-2105. PubMed ID: 26756568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
